A new study conducted in Turku, Finland, reveals how symptoms indicating depression and anxiety are linked to brain function changes already in healthy individuals.
Researchers of the national Turku PET Centre have shown that the opioid system in the brain is connected to mood changes associated with depression and anxiety.
Depression and anxiety are typically associated with lowered mood and decreased experience of pleasure. Opioids regulate the feelings of pain and pleasure in the brain. The new study conducted in Turku shows that the symptoms associated with depression and anxiety are connected to changes in the brain's opioid system already in healthy individuals.
We found that the more depressive and anxious symptoms the subjects had, the less opioid receptors there were in their brain. These receptors function like small "docks" that are influenced by both the brains own opioids as well as opiates. These type of opioid-mediated mood changes can be an important mechanism in the central nervous system. These results show that the mood changes indicating depression can be detected in the brain already early on. Both the brain's own opioids and synthetic opiate-based drugs regulate mood. Based on the results, drugs that have an effect on the opioid system can help in the treatment of depression."
Professor Lauri Nummenmaa, University of Turku
The study was conducted with Positron Emission Tomography (PET) and altogether 135 volunteers participated as subjects. A small dose of radioactive tracer binding to the brain's opioid receptors was injected in their circulation. The decay of the tracers was measured with a PET camera, whereas the depressive and anxious symptoms of the subjects were measured with questionnaires.
The study is based on the AIVO database hosted by Turku University Hospital and Turku PET Centre. The database contains different in vivo molecular brain scans for extensive analyses: https://aivo.utu.fi/
The results have been published in the Neuropsychopharmacology journal.
Nummenmaa, L., et al. (2020) Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety. Neuropsychopharmacology. doi.org/10.1038/s41386-020-0725-9.